NCT00837720

Brief Summary

This open label, non-interventional study is to show the efficacy of antihypertensive treatment with Atacand in hypertensive patients. Efficacy is to be evaluated based on the difference in systolic and diastolic blood pressure at baseline and at both follow-up visits.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
750

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2006

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2006

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2007

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

February 4, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 5, 2009

Completed
Last Updated

February 6, 2009

Status Verified

February 1, 2009

First QC Date

February 4, 2009

Last Update Submit

February 5, 2009

Conditions

Hypertension

Keywords

hypertensionblood pressureAtacand®candesartan

Outcome Measures

Primary Outcomes (1)

  • Systolic and diastolic blood pressure reduction

    12 weeks

Secondary Outcomes (3)

  • Incidence and reasons of treatment discontinuation

    12 weeks

  • Patient treatment satisfaction (using 5-point answering scale) as the measure of the patient's overall tolerance

    12 weeks

  • Physician overall evaluation of the therapy (using 5-point answering scale)

    12 weeks

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients (outpatient or hospitalised) in whom Atacand is indicated according to the current Summary of product characteristics (SPC)

You may not qualify if:

  • hypersensitivity to candesartan or any other ingredient of Atacand
  • liver function impairment and/or cholestasis
  • severe renal insufficiency
  • woman of child-bearing potential and not using appropriate contraceptive measures, pregnancy or lactation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Rok Accetto, MD

    University Medical Centre Ljubljana

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 4, 2009

First Posted

February 5, 2009

Study Start

March 1, 2006

Study Completion

June 1, 2007

Last Updated

February 6, 2009

Record last verified: 2009-02